Clinical data on use of Repatha in Koreans revealed
By Son, Hyung-Min | translator Kang, Shin-Kook
24.04.30 05:48:51
가나다라
0
PCSK9 inhibitor Repatha confirms efficacy in high-risk Korean patients
Rate of LDL-C target level achievement is low despite the use of statins...need additional treatment options
▲Miyoung Song, Cardiology TA Lead and Senior Medical Advisor at Amgen Korea
Amgen's dyslipidemia drug Repatha (evolocumab) has demonstrated LDL-cholesterol reduction in an additional trial conducted on Koreans. Based on the verified results, Amgen Korea emphasized the need for early access to Repatha for high-risk patients whose LDL cholesterol is uncontrolled with statins.Amgen Korea held a press conference at Spaceshare Seoul Station Center on the 29th to introduce the benefits of Repatha in atherosclerotic cardiovascular disease (ASCVD).
ASCVD is caused by the buildup of fatty deposits and cellular waste in the lining of the arteries, which narrows the blood vessels, resulting in uneven blood flow. It includes conditions such as acute coronary syndrome and p
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)